SCHEMBL3530248

SCHEMBL3530248

O=C(CCCCC1CCSS1)NC1CCc2nc(NC(=O)c3ccc(F)cc3)ncc2C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
HTT P42858 1/20 0.40
ACHE P22303 8/20 0.38
BCHE P06276 7/20 0.38
PTPRF P10586 5/20 0.38
PTPN2 P17706 5/20 0.38
PTPN1 P18031 5/20 0.38
HSD17B10 Q99714 2/20 0.36
KMT2A Q03164 2/20 0.36
TARDBP Q13148 2/20 0.36
CYP2C9 P11712 1/20 0.36
MEN1 O00255 1/20 0.36
NR1I2 O75469 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36
THRB P10828 1/20 0.36
TSHR P16473 1/20 0.36
APEX1 P27695 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3527561 0.85 CYP1A2 (0.45) CYP1A2CYP3A4HTTALDH1A1LMNA
SCHEMBL3531823 0.81 CYP1A2 (0.47) CYP1A2CYP3A4HTTKMT2ACYP2C9
SCHEMBL3534801 0.80 CYP1A2 (0.48) CYP1A2CYP3A4HTTCYP2C9ALDH1A1
SCHEMBL3533367 0.78 MEN1 (0.43) CYP1A2CYP3A4HTTACHEKMT2A
SCHEMBL3532765 0.74 CYP1A2 (0.42) CYP1A2CYP3A4HTTKMT2AMEN1
SCHEMBL3530287 0.72 CYP1A2 (0.48) CYP1A2CYP3A4HTTKMT2ACYP2C9
SCHEMBL3531829 0.71 CYP1A2 (0.44) CYP1A2CYP3A4HTTALDH1A1
SCHEMBL3528132 0.71 HDAC8 (0.52) CYP1A2CYP3A4HTTALDH1A1LMNA
SCHEMBL3526674 0.71 CYP1A2 (0.46) CYP1A2CYP3A4HTTALDH1A1LMNA
SCHEMBL3534559 0.71 CYP1A2 (0.46) CYP1A2CYP3A4HTTCYP2C9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1742925-B1 SUBSTITUTED 5, 6, 7, 8-TETRAHYDRO-PYRIDO[4, 3-D]PYRIMIDINE-2-YL COMPOUNDS AND 5, 6, 7, 8-TETRAHYDRO-QUINAZOLINE-2-YL COMPOUNDS GRUENENTHAL GMBH (DE) 2014-04-23 EP claimed
US-20070249631-A1 Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds GRUENENTHAL GMBH (DE) 2007-10-25 US claimed
EP-1742925-B1 SUBSTITUTED 5, 6, 7, 8-TETRAHYDRO-PYRIDO[4, 3-D]PYRIMIDINE-2-YL COMPOUNDS AND 5, 6, 7, 8-TETRAHYDRO-QUINAZOLINE-2-YL COMPOUNDS GRUENENTHAL GMBH (DE) 2014-04-23 EP disclosed
US-7662828-B2 Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds GRUENENTHAL GMBH (DE) 2010-02-16 US disclosed
US-20090176811-A1 Substituted 5,6,7,8-Tetrahydro-pyrido[4,3-d]pyrimidine-2-yl Compounds and 5,6,7,8-Tetrahydro-quinazoline-2-yl Compounds GRUENENTHAL GMBH (DE) 2009-07-09 US disclosed
US-20070249631-A1 Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds GRUENENTHAL GMBH (DE) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249631-A1 Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds P2RX7, CYP2C8, P2RX5 CYP1A2 51/4885CYP3A4 43/4885HTT 858/4885
US-20090176811-A1 Substituted 5,6,7,8-Tetrahydro-pyrido[4,3-d]pyrimidine-2-yl Compounds and 5,6,7,8-Tetrahydro-quinazoline-2-yl Compounds P2RX7, P2RX5, DPYD CYP1A2 47/4885CYP3A4 52/4885HTT 1459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.